Listar por autor "Cleland, John G.F."

Mostrando ítems 1-3 de 3

    • 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 

      McDonagh, Theresa A.; Metra, Marco; Adamo, Marianna; Gardner, Roy S.; Baumbach, Andreas; Böhm, Michael; Burri, Haram; Butler, Javed; Čelutkienė, Jelena; Chioncel, Ovidiu; Cleland, John G.F.; Crespo-Leiro, María Generosa; Farmakis, Dimitrios; Gilard, Martine; Heymans, Stephane; Hoes, Arno W.; Jaarsma, Tiny; Jankowska, Ewa A.; Lainscak, Mitja; Lam, Carolyn S.P.; Lyon, Alexander R.; McMurray, John J.V.; Mebazaa, Alexandre; Mindham, Richard; Muneretto, Claudio; Piepoli, Massimo Francesco; Price, Susanna; Rosano, Giuseppe M.C.; Ruschitzka, Frank; Skibelund, Anne Kathrine (Oxford Academic, 2023-10-01)

    • Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Li, J.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Varin, Claire; Honarpour, N.; Abbasi, Siddique A.; Malik, Fady I.; Kurtz, Christopher E. (Massachusetts Medical Society, 2020-11-13)
      [Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular ...

    • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E. (Willey Online Library, 2020-09-20)
      [Abstract] Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...